The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas

Brain Research Reviews

Volumn 29, Issue 2-3, 1999, Pages 232-249

  Bredel, Markus ^a   Pollack, Ian F ^a  

^a NONE

Author keywords

Apoptosis; Astrocytoma; Cell proliferation; Farnesyltransferase; Geranylgeranyltransferase; Glioblastoma multiforme; Glioma growth; Growth factor; Growth inhibition; High grade glioma; Mutation; p21 Ras overactivation; Signal transduction

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN P21;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; GENE INACTIVATION; GENE MUTATION; GLIOMA; GROWTH REGULATION; HUMAN; MOLECULAR DYNAMICS; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; GLIOMA; HUMANS; ONCOGENE PROTEIN P21(RAS); SIGNAL TRANSDUCTION;

EID: 0032927688     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(98)00057-5     Document Type: Review

References (257)

1. Aaronson S.A. Growth factors and cancer. Science. 254:1991;1146-1153.
2. Aaronson S.A., Miki T., Meyers K., Chan A. Growth factors and malignant transformation. Adv. Exp. Med. Biol. 348:1993;7-22.
3. Adler V., Polotskaya A., Wagner F., Kraft A.S. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J. Biol. Chem. 267:1992;17001-17005.
4. Ahmadian M.R., Wiesmuller L., Lautwein A., Bischoff F.R., Wittinghofer A. Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120-GAP and neurofibromin. J. Biol. Chem. 271:1996;16409-16415.
5. Alessi D.R., Saito Y., Campbell D.G., Cohen P., Sithanandam G., Rapp U., Ashworth A., Marshall C.J., Cowley S. Identification of the sites in MAP kinase kinase-1 phosphorylated by 74-Raf1. EMBO J. 13:1994;1610-1619.
6. Baltensperger K., Kozma L.M., Cherniack A.D., Klarlund J.K., Chawala A., Banerjee U., Czech M.P. Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. Science. 260:1993;1950-1952.
7. Barbacid M. Ras genes. Annu. Rev. Biochem. 56:1987;779-827.
8. Barlat I., Schweighoffer F., Chevallier-Multon M.C., Duchesne M., Fath I., Landais D., Jacquet M., Tocque B. The Saccharomyces cervisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells. Oncogene. 8:1993;215-218.
9. Barnard D., Diaz B., Hettich L., Chuang E., Zhang X.F., Avruch J., Marshall M. Identification of the sites of interaction between c-Raf-1 and Ras-GTP. Oncogene. 10:1995;1283-1290.
10. Bigner S.H., Mark J., Burger P.C., Mahaley S.M., Bullard D.E.J., Muhlbaier L.H., Bigner D.D. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48:1988;405-411.
11. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA. 90:1993;5889-5892.
12. Blin N., Muller-Brechlin R., Carstens C., Meese E., Zang K.D. Enhanced expression of four cellular oncogenes in a human glioblastoma cell line. Cancer Genet. Cytogenet. 25:1987;285-292.
13. Bogler O., Huang H.-J.S., Kleihues P., Cavenee W.K. The p53 gene and its role in human brain tumors. Glia. 15:1995;308-327.
14. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature. 366:1993;643-654.
15. Bollag G., McCormick F. Differential regulation of Ras-GAP and neurofibromatosis gene product activities. Nature. 351:1991;576-579.
16. Bollag G., McCormick F. Regulators and effectors of Ras proteins. Annu. Rev. Cell Biol. 7:1991;601-632.
17. Borowski P., Kornetzky L., Heiland M., Roloff S., Weber W., Laufs R. Characterization of the C-terminal domain of Ras-GTPase-activating protein (Ras-GAP) as substrate for epidermal growth factor receptor and p60 (c-Src) kinase. Biochem. Mol. Biol. Int. 39:1996;635-646.
18. Bos J.L. Ras oncogenes in human cancers: a review. Cancer Res. 49:1989;4682-4689.
19. Bos J.L. Mutational activation of human Ras genes. Nato. ASI Ser. A. 170:1989;15-18.
20. Boulton T.G., Cobb M.H. Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul. 2:1991;357-371.
21. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily: a conserved switch for all diverse functions. Nature. 348:1990;125-132.
22. Bredel M., Pollack I.F. The role of protein kinase C (PKC) in the evolution and proliferation of malignant glioma, and the application of PKC inhibition as a novel approach to anti-glioma-therapy. Acta Neurochir. 139:1997;1000-1013.
23. Bredel M., Pollack I.F., Campbell J.W., Hamilton R.L. Basic fibroblast growth factor (bFGF) expression as a predictor of prognosis in pediatric high-grade gliomas. Clin. Cancer Res. 3:1997;2157-2164.
24. M. Bredel, I.F. Pollack, J.M. Freund, A. Hamilton, S.M. Sebti, P21-Ras Inhibition as a novel therapeutic strategy to block malignant glioma growth, Neurosurgery (in press).
25. Buday L., Downhard J. Epidermal growth factor regulates p21-Ras through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor. Cell. 73:1993;611-620.
26. P.C. Burger, B.W. Scheithauer, F.S. Vogel, (Eds.), Surgical Pathology of the Nervous System and Its Coverings, 3rd edn., Churchill Livingstone, New York, pp. 194-271.
27. Caldas C., Kern S.E. K-Ras mutation and pancreatic adenocarcinoma. Int. J. Pancreatol. 18:1995;1-6.
28. Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., Soltoff S. Oncogenes and signal transduction. Cell. 64:1991;281-302.
29. Carroll R.S., Zhang J., Chauncey B.W., Chantziara K., Frosch M.P., Black P.McL. Apoptosis in astrocytic neoplasms. Acta Neurochir. 139:1997;845-850.
30. Casay P.J. Biochemistry of protein prenylation. J. Lipid Res. 33:1992;1731-1740.
31. Casay P.J., Solski P.A., Der C.J., Buss J.E. p21-Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA. 86:1989;8323-8327.
32. Cen H., Papageorge A.G., Vass W.C., Zhang K., Lowy D.R. Regulated and constitutive activity by CDC25MM (GRF), a Ras-specific exchange factor. Mol. Cell Biol. 13:1993;7718-7724.
33. Chao T.-S.O., Foster D.A., Rapp U.R., Rosner M.R. Differential Raf requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters, and calcium. J. Biol. Chem. 269:1994;7337-7341.
34. Chardin P., Camonis J.H., Gale N.W., van Aelst L., Schlessinger J., Wigler M.H., Bar-Sagi D. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 260:1993;1338-1343.
35. Chen C.Y., Faller D.V. Directions of p21-Ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene. 11:1995;1487-1498.
36. Chen D., Waters S.B., Holt K.H., Pessin J.E. Sos phosphorylation and dissociation of the Grb2-Sos complex by the ERK and JNK signaling pathways. J. Biol. Chem. 271:1996;6328-6332.
37. Chen R.H., Sarnecki C., Blenis J. Nuclear localization and regulation of ERK- and RSK-encoded protein kinases. Mol. Cell Biol. 12:1992;915-927.
38. Clark G.J., Hisaka M.M., Abe K., Der C.J. Differential antagonism of Ras biological activity by the Ras GAP catalytic and SH2/SH3 domains. Proc. Am. Assoc. Cancer Res. 33:1992;A2369.
39. Cook S.J., Rubinfeld B., Albert I., McCormick F. RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J. 12:1993;3475-3485.
40. Cox A.D., Der C.J. Protein prenyalation: more than just glue? Curr. Opin. Cell Biol. 4:1992;1008-1016.
41. Crews C.M., Erikson R.L. Extracellular signals and reversible protein phosphorylation: what to MEK of it all. Cell. 74:1993;215-217.
42. Crews C.M., Alessandrini A., Erikson R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 258:1992;478.
43. Cullen P.J., Hsuan J.J., Truong O., Letcher A.J., Jackson T.R., Dawson A.P., Irvine R.F. Identification of a specific Ins(1,3,4,5)P4-binding protein as a member of the GAP1 family. Nature. 376:1995;527-530.
44. Davis R.L. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:1993;14553-14556.
45. Debiec-Rychter M., Liberski P.P. Molecular changes involved in the carcinogenesis of brain tumors. Folia Neuropathol. 32:1994;199-203.
46. DeClue J.E., Vass W.C., Papageorge A.G., Lowy D.R., Willumsen B.M. Inhibition of cell growth by lovastatin is independent of Ras function. Cancer Res. 51:1991;712-717.
47. Defeo-Jones D., McAvoy E.M., Jones R.E., Vuocolo G.A., Haskell K.M., Wegrzyn R.J., Oliff A. Lovastatin selectively inhibits Ras activation of the 12-O-tetradecanoylphorbol-13-acetate response element in mammalian cells. Mol. Cell Biol. 11:1991;2307-2310.
48. von Deimling A., Louis D.N., von Ammon K., Petersen I., Hoell T., Chung R.Y., Martuza R., Schoenfeld D., Yasaragil M.G., Wiestler O.D., Seizinger B.R. Association of epidermal growth factor receptor gene amplification with loss of chromsome 10 in human glioblastoma multiforme. J. Neurosurg. 77:1992;295-301.
49. Denmeade S.R., Isaacs J.T. Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control. 3:1996;303-309.
50. Dent P., Haser W., Haystead T.A., Vincent L.A., Roberts T.M., Sturgill T.W. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH3T3 cells and in vitro. Science. 257:1992;1404-1407.
51. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologues to the Ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. USA. 79:1982;3637-3640.
52. De Vries Smits A.M., Burgering B.M., Leevers S.J., Marshall C.J., Bos J.L. Involvement of p21-Ras in activation of extracellular signal-regulated kinase 2. Nature. 357:1992;602-604.
53. Dickson B., Sprenger F., Morrison D., Hafen E. Raf functions downstream of Ras1 in the sevenless signal transduction pathway. Nature. 360:1992;600-603.
54. Dietrich U., Lucius J., Baron E., Behnke J., Pabst B., Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumors and correlation to prognosis. J. Neurol. 242:1995;683-688.
55. Di Jeso B., Ulianich L., Racioppi L., D'Armiento F., Feliciello A., Pacifico F., Consiglio E., Formisano S. Serum withdrawal induces apoptotic cell death in K-Ras transformed but not in normal differentiated tyroid cells. Biochem. Biophys. Res. Commun. 214:1995;819-824.
56. Di Marco E., Pierce J.H., Aaronson S.A., Di Fiore P.P. Mechanisms by which EGF receptor and TGF alpha contribute to malignant transformation. Nat. Immun. Cell Growth. Regul. 9:1990;209-221.
57. Dohrman G.J., Farwell J.R., Flannery J.T. Gliobastoma multiforme in children. J. Neurosurg. 44:1976;442-448.
58. Downward J. Regulation of p21Ras by GTPase activating proteins and guanine nucleotide exchange proteins. Curr. Opin. Genet. Dev. 2:1992;13-18.
59. Downward J. Regulatory mechanisms for Ras proteins. Bioessays. 14:1992;177-184.
60. Dropcho E., Wisoff J., Walker R., Allen J.C. Supratentorial malignant gliomas in childhood: a review of fifty cases. Ann. Neurol. 22:1978;355-364.
61. Drugan J.K., Khosravi-Far R., White M.A., Der C.J., Sung Y.J., Hwang Y.W., Campbell S.L. Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. J. Biol. Chem. 271:1996;233-237.
62. Egan S.E., Giddings B.W., Brooks M.W., Buday L., Sizeland A.M., Weinberg R.A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature. 363:1993;45-51.
63. Ekstrand A.J., James C.D., Cavenee W.K., Seliger B., Pettersson R.F., Collins V.P. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:1991;2164-2172.
64. Evans V.G. Multiple pathways to apoptosis. Cell Biol. Int. 17:1993;461-476.
65. Fakhrai H., Dorigo O., Shawler D.L., Lin H., Mischel P., Black K.L., Roysten I., Sobol R.E. Immunization with TGF-beta-2 antisense gene modified tumor cells eradicates intracranial gliomas. Proc. Am. Assoc. Cancer Res. 14:1995;A2756.
66. Farrar M.A., Alberola-Ila J., Perlmutter R.M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature. 383:1996;178-181.
67. Farrell F.X., Yamamoto K., Lapetina E.G. Prenyl group identification of rap2 proteins: a Ras superfamily member other than Ras that is farnesylated. Biochem. J. 289:1993;349-355.
68. Feldkamp M.M., Lau N., Guha A. Signal transduction pathways and their relevance in human astrocytomas. J. Neuro.-Oncol. 35:1997;223-248.
69. Feldkamp M.M., Lau N., Guha A. Astrocytomas are growth-inhibited by farnesyl transferase inhibitors despite the absence of oncogenic Ras mutations. Proc. Am. Assoc. Cancer Res. 38:1997;A351.
70. Feldkamp M.M., Lau N., Guha A. A mutant epidermal growth factor receptor (p140EGF-R) confers a growth advantage to astrocytoma cell lines and results in increased Ras pathway activity. Proc. Am. Assoc. Cancer Res. 38:1997;A620.
71. Feldkamp M.M., Rak J., Lau N., Kerbel R.S., Guha A. Astrocytomas express high levels of vascular endothelial growth factor (VEGF) which are reduced through Ras pathway inhibition. Clin. Neurol. Neurosurg. 99:1997;A5.
72. Fernandez R.S., McGowan A.J., Cotter T.G. Mutant H-Ras overexpression inhibits drug and U.V. induced apoptosis. Anticancer Res. 16:1996;1691-1705.
73. Fults D., Pedone C.A., Thomas G.A., White R. Allelotype of human malignant astrocytomas. Cancer Res. 50:1990;5784-5789.
74. Fults D., Petronio J., Noblett B.D., Pedone C.A. Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics. 14:1992;799-801.
75. Gale N.W., Kaplan S., Lowenstein E.J., Schlessinger J., Bar-Sagi D. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature. 363:1993;88-92.
76. Gately S., Soff G.A., Brem S. The potential role of basic fibroblast growth factor in the transformation of cultured primary human fetal astrocytes and the proliferation of human glioma (U-87) cells. Neurosurgery. 37:1995;723-730.
77. Georges R.N., Mukhopadhyay T., Zhang Y., Yen N., Roth J.A. Prevention of orthotopic human lung cancer growth by intratracheal installation of a retroviral antisense K-Ras construct. Cancer Res. 53:1993;1743-1746.
78. Gerosa M.A., Talarico D., Fognani C., Raimondi E., Colombatti M., Tridente G., De Carli L., Della Valle G. Overexpression of N-Ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J.N.C.I. 81:1989;63-67.
79. Gibbs J.B. Ras C-terminal processing enzymes - new drug targets? Cell. 65:1991;1-4.
80. Gibbs J.B. Pharmacological probes of Ras function. Semin. Cancer Biol. 3:1992;383-390.
81. Gibbs J.B., Kohl N.E., Koblan K.S., Omer C.A., Sepp-Lorenzino L., Rosen N., Anthony N.J., Conner M.W., DeSolms S.J., Williams T.M., Graham S.L., Hartman G.D., Oliff A. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat. 38:1996;75-83.
82. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
83. Gibbs J.B., Pompliano D.L., Mosser S.D., Rands E., Lingham R.B., Singh S.B., Scolnick E.M., Kohl N.E., Oliff A. Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J. Biol. Chem. 268:1993;7617-7620.
84. Gillaspy G.E., Mapstone T.B., Samols D., Goldthwait D.A. Transcriptional patterns of growth factors and proto-oncogenes in human glioblastomas and normal glial cells. Cancer Lett. 65:1992;55-60.
85. Gille H., Kortenjahn M., Thomae O., Moomaw C., Slaughter C., Cobb M.H., Shaw P.E. ERK phosphorylation potentiates Elk-1-mediated tenary complex formation and transactivation. EMBO J. 14:1995;951-962.
86. Ginty D.D., Bonni A., Greenberg M.E. Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-Fos transcription via phosphorylation of CREB. Cell. 77:1994;713-725.
87. Glick R.P., Unterman T.G., Hollis R. Radioimmunoassay of insulin-like growth factor in cyst fluid of central nervous system tumors. J. Neurosurg. 74:1991;972-978.
88. Glomset J.A., Gelb M.H., Farnsworth C.C. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. 15:1990;139-142.
89. Gomez J., Martinez C., Fernandez B., Garcia A., Rebollo A. Critical role of Ras in the proliferation and prevention of apoptosis mediated by IL-2. J. Immunol. 157:1996;2272-2281.
90. Gonzalez F.A., Raden D.L., Davis R.J. Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J. Biol. Chem. 266:1991;22159-22163.
91. Graham S.L., DeSolms S.J., Giuliani E.A., Kohl N.E., Mosser S.D., Oliff A., Pompliano D.L., Rands E., Breslin M.J., Deana A.A.et al. Pseudopeptide inhibitors of Ras franesyl protein transferase. J. Med. Chem. 37:1994;725-732.
92. Guha A., Lau N., Gutmann D., Provias J., Pawson T., Boss G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 12:1996;507-513.
93. Guha A., Lau N., Pawson A. Ras-mediated proliferation of human astrocytoma cells. Proc. Am. Assoc. Cancer Res. 36:1995;A1029.
94. Gutmann D.H., Giordano M.J., Mahadeo D.K., Lau N., Silbergeld D., Guha A. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-Ras. Oncogene. 12:1996;2121-2127.
95. Hall A. Ras and GAP - who's controlling whom. Cell. 61:1990;921-923.
96. Hallberg B., Rayter S.I., Downward J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J. Biol. Chem. 269:1994;3913-3916.
97. Hancock J.F., Magee A.I., Childs J.E., Marshall C.J. All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 57:1989;1167-1177.
98. Hancock J.F., Paterson H., Marshall J.C. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21-Ras to the plasma membrane. Cell. 63:1990;133-139.
99. Harvey J.J. An unidentified virus which causes the rapid production of tumors in mice. Nature. 204:1964;1104-1105.
100. Hill C.S., Marais R., John S., Wynne J., Dalton S., Treisman R. Functional analysis of a growth factor-responsive transcription factor complex. Cell. 73:1993;395-406.
101. Howe L.R., Leevers S.J., Gomez N., Nakielny S., Cohen P., Marshall C.J. Activation of the MAP kinase by the protein kinase Raf. Cell. 71:1992;335-342.
102. Jachimczak P., Fabel-Schulte K., Hessdorfer B., Baur I., Brysch W., Schlingensiepen K.H., Bogdahn U. Transforming growth factor beta-mediated crosstalk between glioma cells and peripheral blood mononuclear cells in vitro. Proc. Am. Assoc. Cancer Res. 36:1995;A2856.
103. Jachimczak P., Hessdorfer B., Fabel-Schulte K., Wismeth C., Brysch W., Schlingensiepen K.H., Bauer A., Blesch A., Bogdahn U. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Intl. J. Cancer. 65:1996;332-337.
104. Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesyl modification of Kirsten-Ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA. 87:1990;3042-3046.
105. James C.D., Carlblom E., Dumanski J.P., Hansen M., Nordenskjold M., Collins V.P., Cavenee W.K. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 48:1988;5546-5551.
106. James G.L., Brown M.S., Cobb M.H., Goldstein J.L. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J. Biol. Chem. 269:1994;27705-27714.
107. James G.L., Goldstein J.L., Brown M.S., Rawson T.E., Somers T.C., McDowell R.S., Crowley C.W., Lucas B.K., Levinson A.D., Marsters J.C. Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260:1993;1937-1942.
108. Johnson B.E., Kelley M.J. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest. 103:1993;1-3.
109. Kato K., Cox A.D., Hisaka M.M., Graham S.M., Buss J.E., Der C.J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA. 89:1992;6403-6407.
110. Kavanaugh W.M., Turck C.W., Williams L.T. PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine. Science. 268:1995;1177-1179.
111. Kerr J., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-257.
112. Kirsten W.H., Mayer L.A. Morphologic responses to a murine erythroblastosis virus. J. Natl. Cancer Inst. 39:1967;311-335.
113. Kleisbauer J.P., Thomas P. Prognostic factors of lung cancer. Rev. Prat. 43:1993;852-855.
114. Klingshoffer R.A., Duckworth B., Valius M., Cantley L., Kazlauskas A. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol. Cell Biol. 16:1996;5905-5914.
115. Koch C.A., Anderson D., Moran M.F., Ellis C., Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science. 252:1991;668-674.
116. Kohl N.E., Conner M.W., Gibbs J.B., Graham S.L., Hartman G.D., Oliff A. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J. Biol. Chem. 22:1995;145-150. (Suppl.).
117. Kohl N.E., Mosser S.D., DeSolms S.J., Giuliani E.A., Pomliano D.L., Graham S.L., Smith R.L., Scolnick E.M., Oliff A., Gibbs J.B. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
118. Kohl N.E., Wilson F.R., Mosser S.D., Giuliani E., DeSolms S.J., Conner M.W., Anthony N.J., Holtz W.J., Gomez R.P., Lee T.-J., Smith R.L., Graham S.L., Hartmann G.D., Gibbs J.B., Oliff A. Protein farnesyltransferase inhibitors block the growth of Ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA. 91:1994;9141-9145.
119. Krueger G.R., Buja L.M., Rojo J., Lasch J., Koch B., Leyssens N. Apoptosis and cell proliferation in HHV-6 infections. Regulatory mechanisms of p53/bcl-2/Ras interactions. Pathology. 16:1995;120-127.
120. Kyriakis J.M., App H., Zhang X.F., Banerjee P., Brautigan D.L., Rapp V.R., Avruch J. Raf-1 activates MAP kinase kinase. Nature. 358:1992;417-421.
121. Lai C.-C., Boguski M., Broek D., Powers S. Influence of guanine nucleotides on complex formation between Ras and CDC25 protein. Mol. Cell Biol. 13:1993;1345-1352.
122. Lang F.F., Miller C.C., Koslow M., Newcomb E.W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 81:1994;427-436.
123. Lange-Carter C.A., Johnson G.L. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science. 265:1994;1458-1461.
124. Leevers S.L., Marshall C.J. Activation of extracelluar signal-regulated kinase, ERK2, by p21-Ras oncoproteins. EMBO J. 11:1992;569-574.
125. Lenormand P., Sardet C., Pages G., L'Allemain G., Brunet A., Pouyssegur J. Growth factors induce nuclear translocation of MAP kinases (p42-Mapk and p44-Mapk) but not of their activator MAPK kinase kinase (p45-Mapkk) in fibroblasts. J. Cell Biol. 122:1993;1079-1088.
126. Lerner E.C., Qian Y., Blaskovitch M.A., Fossum R.D., Vogt A., Sun J., Cox A.D., Der C.J., Hamilton A.D., Sebti S.M. Ras CAAX peptidomimetic FTI-277 blocks oncongenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270:1995;26802-26806.
127. Lerner E.C., Qian Y., Hamilton A.D., Sebti S.M. Disruption of oncongenic K-Ras-4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270:1995;26770-26773.
128. Lerner E.C., Zhang T.T., Qian Y., Hamilton A.D., Sebti S.M. Inhibition of K-Ras but not H- or N-Ras prenylation requires both farnesyltransferase and geranylgeranyltransferase I inhibitors in human tumor cell lines. Proc. Am. Assoc. Cancer Res. 38:1997;A352.
129. Li N., Batzer A., Daly R., Yajnik V., Skolnik E., Chardin P., Bar-Sagi D., Margolis B., Schlessinger J. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling. Nature. 363:1993;85-88.
130. Li P., Wood K., Mamon H., Haser W., Roberts T. Raf-1: A kinase currently without a cause but not lacking effects. Cell. 64:1991;479-482.
131. Li S., Janosch P., Tanji M., Rosenfeld G.C., Waymire J.C., Mischak H., Kolch W., Sedivy J.M. Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. EMBO J. 14:1995;685-696.
132. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature. 313:1985;144-147.
133. Lin H.J., Eviner V., Prendergast G.C., White E. Activated H-Ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell Biol. 15:1995;4536-4544.
134. Lipeski L.E., Boylan J.M., Gruppuso P.A. A comparison of epidermal growth factor receptor-mediated mitogenic signaling in response to transforming growth factor alpha and epidermal growth factor in cultured fetal rat hepatocytes. Biochem. Mol. Biol. Int. 39:1996;975-983.
135. Longnecker D.S., Memoli V., Pettengill O.S. Recent results in animal models of pancreatic carcinoma: histogenesis of tumors. Yale J. Biol. Med. 65:1992;457-464.
136. Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E.Y., Bar-Sagi D., Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to Ras signaling. Cell. 70:1992;431-442.
137. Lowy D.R., Willumsen B.M. Function and regulation of Ras. Annu. Rev. Biochem. 62:1993;851-891.
138. Lundy J., Chen J., Wang P., Fromowitz F., Schuss A., Lynch S., Brugge J., Viola M.V. Phenotypic and genetic alterations in pre-cancerous cells in the colon. Anticancer Res. 8:1988;1005-1013.
139. Luo Z., Tzivion G., Belshaw P.J., Vavvas D., Marshall M., Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature. 383:1996;181-185.
140. Macara I.G., Lounsbury K.M., Richards S.A., McKiernan C., Bar-Sagi D. The Ras superfamily of GTPases. FASEB J. 10:1996;625-630.
141. Macdonald S.G., Crews C.M., Wu L., Driller J., Clark R., Erikson R.L., McCormick F. Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol. Cell Biol. 13:1993;6615-6620.
142. Maekawa M., Li S., Iwamatsu A., Morishita T., Yokota K., Imai Y., Kohsaka S., Nakamura S., Hattori S. A novel mammalian Ras GTPase-activating protein which has phospholipid-binding and Btk homology regions. Mol. Cell Biol. 14:1994;6879-6885.
143. Magee A.I., Gutierrez L., McKay I.A., Marshall C.J., Hall A. Dynamic fatty acylation of p21-N-Ras. EMBO J. 6:1987;3353-3357.
144. Maltzman T.H., Mueller B.A., Schroeder J., Rutledge J.C., Patterson K., Preston-Martin S., Faustman E.M. Ras oncogene mutations in childhood brain tumors. Cancer Epidemiol. Biomarkers Prev. 6:1997;239-243.
145. Manne V., Roberts D., Tobin A., O'Rourke E., De Virgilio M., Meyers C., Ahmed N., Kurz B., Resh M., Kung H.F.et al. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. USA. 87:1990;7541-7545.
146. Manne V., Yan N., Carboni J.M., Tuomari A.V., Ricca C.S., Brown J.G., Andahazy M.L., Schmidt R.J., Patel D., Zahler R., Weinmann R., Der C.J., Cox A.D., Hunt J.T., Gordon E.M., Barbacid M., Seizinger B.R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of Ras transformed cells. Oncogene. 10:1995;1763-1779.
147. Marais R., Wynne J., Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 73:1993;381-393.
148. Maronpot R.R., Fox T., Malarkey D.E., Goldsworthy T.L. Muations in the Ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology. 101:1995;125-156.
149. Marshall C.J. Raf gets it together. Nature. 383:1996;127-128.
150. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4:1994;82-89.
151. Marshall C.J. Protein prenylation: a mediator of protein-protein interactions. Science. 259:1993;1865-1866.
152. Marshall M. Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Mol. Reprod. Dev. 42:1995;493-499.
153. Maxwell M., Naber S.P., Wolfe H.J., Galanopoulos T., Hedley-Whyte E.T., Black P.M., Antoniades N.H. Co-expression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintainance. J. Clin. Invest. 86:1990;131-140.
154. McCormick F. Ras signaling and NF1. Curr. Opin. Genet. Dev. 5:1995;51-55.
155. McCormick F. Activators and effectors of Ras p21 proteins. Curr. Opin. Genet. Dev. 4:1994;71-76.
156. McCormick F. How receptors turn Ras on. Nature. 363:1993;15-16.
157. McCormick F. The GTPase superfamily. Introduction. Ciba Found. Symp. 176:1993;1-5.
158. Melnyk A., Albitar M., Bartram C., Oliff A., Andreeff M. In-vitro effects of the farnesyltransferase inhibitor '749 on leukemic cell lines with Ras mutations and myelodysplastic syndrome (MDS) patients' samples with and without Ras mutations. Proc. Am. Assoc. Cancer Res. 37:1996;A2875.
159. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 260:1993;1658-1660.
160. Moodie S.A., Wolfman A. The 3Rs of life: Ras, Raf and growth regulation. Trends Genet. 10:1994;44-48.
161. Moore J., Boswell S., Hoffman R., Burgess G., Hromas R. Muant H-Ras overexpression inhibits a random apoptotic nuclease in myeloid leukemia cells. Leuk. Res. 17:1993;703-709.
162. Moores S.L., Schaber M.D., Mosser S.D., Rands E., O'Hara M.B., Garsky V.M., Marshall M.S., Pompliano D.L., Gibbs J.B. Sequence dependence of protein isoprenylation. J. Biol. Chem. 266:1991;14603-14610.
163. Morrison R.S., Giordano S., Yamaguchi F., Hendrickson S., Berger M.S., Palczewski K. Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J. Neurosci. Res. 34:1993;502-509.
164. Nassar N., Horn G., Scherer A., McCormick F., Wittinghofer A. The 2.2A crystal structure of Rhe Ras-binding domain of the serine/threonine kinase c-Rafl in complex with RaplA and a GTP analogue. Nature. 375:1995;554-560.
165. Newman C.M., Magee A.I. Posttranslational processing of the Ras superfamily of small GTP-binding proteins. Biochem. Biophys. Acta. 1155:1993;79-96.
166. Nigam M., Seong C.M., Qian Y., Hamilton D.A., Sebti S.M. Potent inhibition of human tumor p21-Ras farnesyltransferase by A1A2-lacking p21-Ras CA1A2X peptidomimetics. J. Biol. Chem. 268:1993;20695-20698.
167. Nishida E., Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18:1993;128-131.
168. Nister M., Claesson-Welch L., Eriksson A., Heldin C.-H., Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. 266:1991;16755-16763.
169. Nooter K., Boersma A.W., Oostrum R.G., Burger H., Jochemsen A.G., Stoter G. Constitutive expression of the c-H-Ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br. J. Cancer. 71:1995;555-561.
170. Ohgaki H., Schauble B., zur Hausen A., von Ammon K., Kleihues P. The role of transformation-associated genes in the evolution of astrocytic brain tumors. Virchows Arch. 427:1995;113-118.
171. Olivier J.P., Raabe T., Henkemeyer M., Dickson B., Mbamulu G., Margolis B., Schlessinger J., Hafen E., Pawson T. A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell. 73:1993;179-191.
172. Olopade O., Bohlander S., Pomykala H., Maltepe E., Van Melle E., Le Beau M., Diaz M. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics. 14:1992;437-443.
173. Oosterhuis J.W., Olie A., Dekker M.C., Nooter K., Top B., Looijenga L.H. The role of apoptosis and Ras mutations in the in vitro behavior of human seminoma cells. Proc. Am. Assoc. Cancer Res. 36:1995;A31.
174. Orian J.M., Vasilopoulos K., Yoshida S., Kaye A.H., Chow C.W., Gonzales M.F. Overexpression of multiple oncogenes related to histopathological grade of astrocystic glioma. Br. J. Cancer. 66:1992;106-112.
175. Pai J.J., Bishop W.R., Catino J., Kirschmeier P., Whyte D. Characterization of prenyl groups attached to K-Ras in DLD-1 human colon carcinoma cells treated with the FPT inhibitor SCH 44342. Proc. Am. Assoc. Cancer Res. 37:1996;503.
176. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus Ras gene. Nature. 297:1982;474-478.
177. Peddanna N., Holt S., Verma R.S. Genetics of gastric cancer. Anticancer Res. 15:1995;2055-2064.
178. Peddanna N., Mendis R., Holt S., Verma R.S. Genetics of colorectal cancer. Int. J. Oncol. 9:1996;327-335.
179. Pendergast A.M., Quilliam L.A., Cripe L.D., Bassing C.H., Dai Z., Li N., Batzer A., Rabun K.M., Der C.J., Schlessinger J., Gishizky M.L. Bcr-Abl-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb2 adaptor protein. Cell. 75:1993;175-185.
180. Pilkington G.J. Mechanisms underlying local invasive behavior of brain tumors. Anticancer Res. 15:1995;1675-1676.
181. Pinto M.M., Emanuel J.R., Chaturvedi V., Costa J. K-Ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytol. 41:1997;427-434.
182. Pollack I.F. Current concepts in the diagnosis and treatment of pediatric brain tumors. New Engl. J. Med. 331:1994;1500-1507.
183. Pollack I.F., Randall M.S., Kristofik M.P., Kelly R.H., Selker R.G., Vertosick F.T. Jr. Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium. J. Neurosurg. 73:1990;106-112.
184. Pollack I.F., Randall M.S., Kristofik M.P., Kelly R.H., Selker R.G., Vertosick F.T. Jr. Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J. Neurosurg. 75:1991;284-293.
185. Prigent S.A., Nagane M., Lin H., Huvar I., Boss G.R., Feramisco J.R.,
186. Qian Y., Blaskovitch M.A., Saleem M., Seong C.M., Wathen S.P., Hamilton A.D., Sebti S.M. Design and structural requirements of potent peptidomimetic inhibitors of p21-Ras farnesyltransferase. J. Biol. Chem. 269:1994;12410-12413.
187. Radner H., El Shabrawi Y., Eibl R.H., Brustle O., Kenner L., Kleihues P., Wiestler O.D. Tumor induction by Ras and Myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose. Acta Neuropathol. 86:1993;456-465.
188. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:1993;2736-2739.
189. Reiss Y., Goldstein J.L., Seabra M.C., Casey P.J., Brown M.S. Inhibition of purified p21-Ras farnesylproteintransferase by Cys-AAX tetrapeptides. Cell. 62:1990;81-88.
190. Reiss Y., Seabra M.C., Armstrong S.A., Slaughter C.A., Goldstein J.L., Brown M.S. Nonidentical subunits of p21-H-Ras farnesyltransferase. Peptide binding and farnesyl pyrophosphate carrier functions. J. Biol. Chem. 266:1991;10672-10677.
191. Reiss Y., Stradley S.J., Gierasch L.M., Brown M.S., Goldstein J.L. Sequence requirement for peptide recognition by rat brain p21-Ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA. 88:1991;732-736.
192. Ren R., Mayer B.J., Cicchetti P., Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science. 259:1993;1157-1161.
193. Riccardi A., Danova M., Giordano M., Gaetani P., Butti G., Zibera C., Mazzini G. Proto-oncogene expression and proliferative activity in human malignant gliomas. Dev. Oncol. 66:1991;81-84.
194. Ritland S.R., Vinod G., Jenkins R.B. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chrom. Cancer. 12:1995;277-287.
195. Roche S., McGlade J., Jones M., Gish G.D., Pawson T., Courtneidge S.A. Requirement of phospholipase C-gamma, the tyrosine phosphatase SYP and the adaptor proteins SHC and NCK for PDGF-induced DNA synthesis - evidence for the existence of Ras-dependent and Ras-independent pathways. EMBO J. 15:1996;4940-4948.
196. Rodenhuis S., Slebos R.J. Clinical significance of Ras oncogene activation in human lung cancer. Cancer Res. 52:1992;2665-2669.
197. Rowell C., Kowalczyk J., Lewis M.D., Garcia A.M. In vivo prenylation of K-Ras: effect of the farnesyl transferase inhibitor B956. Proc. Am. Assoc. Cancer Res. 38:1997;A351.
198. Rozakis-Adcock M., Fernley R., Wade J., Pawson T., Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 363:1993;83-85.
199. Rozakis-Adcock M., McGlade J., Mbamalu G., Pelicci G., Daly R., Li W., Batzer A., Thomas S., Brugge J., Pelicci P., Schlessinger J., Pawson T. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature. 360:1992;689-692.
200. Rozakis-Adcock M., Van der Geer P., Mbamalu G., Pawson T. MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1-Shc and mSos1-EGF receptor complexes. Oncogene. 11:1995;1417-1426.
201. Sadowski I., Stone J.C., Pawson T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinase modifies the kinase function and transforming activity of Fujinami sarcoma virus. Mol. Cell Biol. 6:1986;4396-4408.
202. Sakai N., Ogiso Y., Fujita H., Watari H., Koike T., Kuzumaki N. Induction of apoptosis by a dominant negative H-Ras mutant (116Y) in K562 cells. Exp. Cell Res. 215:1994;131-136.
203. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:1996;393-401.
204. Salgaller M., Agius L., Yates A., Pearl D., Roberts W., Stephens R. Application of automated image analysis to demonstrate the correlation between Ras p21 expression and severity of glioma, Biochem. Biophys. Res. Commun. 169:1990;482-491.
205. Santos E., Tronick S.R., Aaronson S.A., Pulciani S., Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature. 298:1982;343-347.
206. Satoh T., Nakafuku M., Kaziro Y. Function of Ras as a molecular switch in signal transduction. J. Biol. Chem. 267:1992;24149-24152.
207. Schober R., Bilzer T., Waha A., Reifenberger G., Wechsler W., von Deimling A., Wiestler O.D., Westphal M., Kemshead J.T., Vega F.et al. The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin. Neuropathol. 14:1995;169-174.
208. Scott F.M., Modali R., Lehman T.A., Seddon M., Kelly K., Dempsey E.C., Wilson V., Tockman M.S., Mulshine J.L. High frequency of K-Ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin. Cancer Res. 3:1997;479-482.
209. Seabra M.C., Reiss Y., Casey P.J., Brown M.S., Goldstein J.L. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell. 65:1991;429-434.
210. Seger R., Ahu N.G., Posada J., Munar E.S., Jensen A.M., Cooper J.A., Cobb M.H., Krebs E.G. Purification and characterization of mitogen-activated protein kinase activators from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. 267:1992;14373-14381.
211. Sepp-Lorenzino L., Bos M., Ma Z., Baselga J., Rands E., Kohl N.E., Oliff A., Mendelsohn J., Rosen N. Farnesyl: protein transferase inhibitors (FTIs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth. Proc. Am. Assoc. Cancer Res. 37:1996;A2877.
212. Sepp-Lorenzino L., Ma Z., Rands E., Kohl N.E., Gibbs J.B., Oliff A., Rosen N. A peptidomimetic inhibitor of farnesylprotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
213. Shou C., Farnsworth C.L., Neel B.G., Feig L.A. Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21. Nature. 358:1992;351-354.
214. Simon M.A., Dodson G.S., Rubin G.M. An SH3-SH2-SH3 protein is required for p21-Ras activation and binds to sevenless and Sos proteins in vitro. Cell. 73:1993;169-177.
215. Sjodahl R., Nystrom P.O. Genetic aspects of colorectal cancer: The surgeon's view. Scand. J. Gastroenterol. 220:1996;132-136. (Suppl.).
216. Smith M.R., DeGudicibus S.J., Stacey D.W. Requirement for c-Ras proteins during viral oncogene transformation. Nature. 320:1986;540-543.
217. Songyang Z., Shoeson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., King F., Roberts T., Ratnofsky S., Lechleider R.J.et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 72:1993;767-778.
218. Stephenson J., Mufti G.J., Yoshida Y. Myelodysplastic syndromes: from morphology to molecular biology: Part II. The molecular genetics of myelodysplasia. Int. J. Hematol. 57:1993;99-112.
219. Stokoe D., MacDonald S.G., Cadwallader K., Symons M., Hancock J.F. Activation of Raf as a result of recruitment of the plasma membrane. Science. 264:1994;1463-1467.
220. Sun H., Tonks N.K. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem. Sci. 19:1994;480-485.
221. Sun J., Qian Y., Hamilton A.D., Sebti S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for disruption of K-Ras prenylation but each alone is sufficient for inhibition of human tumor growth. Proc. Am. Assoc. Cancer Res. 38:1997;A352.
222. Sun J., Qian Y., Hamilton A.D., Sebti S.M. Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletio. Cancer Res. 55:1995;4243-4247.
223. Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci. 18:1993;349-353.
224. Thibault A., Cooper M.R., Figg W.D., Weinberger M.S., Tompkins A.C., Trepel J., Samid D., Myers C.E. A Phase I trial of high-dose lovastatin shows ativitiy against malignant astrocytomas. Proc. Am. Assoc. Cancer Res. 35:1994;A1351.
225. Thomas S.M., DeMarco M., D'Arcangelo G., Halegona S., Brugge J.S. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell. 68:1992;1031-1040.
226. Tsuda T., Marinetti M.R., Masuelli L., Cutler M.L. The Ras suppressor RSU-1 localizes to 10p13 and its expression in the U251 glioblastoma cell line correlated with a decrease in growth rate and tumorigenic potential. Oncogene. 11:1995;397-403.
227. Tsurushima H., Tsuboi K., Yoshii Y., Ohno T., Meguro K., Nose T. Expression of N-Ras gene in gliomas. Neurol. Med. Chir. 36:1996;704-708.
228. Tuzi N.L., Uenter D.J., Kumar S., Staddon S.L., Lemoine N.R., Gullick W.J. Expression of growth factor receptors in human brain tumors. Br. J. Cancer. 63:1991;227-233.
229. Van Blesen T., Hawes B.E., Luttrell D.K., Krueger K.M., Touhara K., Profiri E., Sakaue M., Luttrell L.M., Lefkowitz R.J. Receptor-tyrosine-kinase- and G-beta-gamma-mediated MAP kinase activation by a common signaling pathway. Nature. 376:1995;781-784.
230. Van de Kleft E. Molecular pathogenesis of astrocytoma and glioblastoma multiforme. Acta Neurochir. 139:1997;589-599.
231. Van der Valk P., De Moor I., Kamphorst W., Meijer C.J. Autocrine and paracrine growth in gliomas. J. Pathol. 175:1995;A106. (Suppl.).
232. Vassbotn F.S., Ostman A., Langeland N., Holmsen H., Westermark B., Heldin C.H., Nister M. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J. Cell. Physiol. 158:1994;381-389.
233. Vogt A., Qian Y., Blaskovich M.A., Fossum R.D., Hamilton A.D., Sebti S.M. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem. 270:1995;660-664.
234. Voijek A.B., Hollenberg S.M., Cooper J.A. Mammalian Ras interacts with the serine/threonine kinase Raf. Cell. 74:1993;205-214.
235. Wanebo H.J., Vezeridis M.P. Pancreatic carcinoma in perspective, a continuing challenge. Cancer. 78:1996;580-591.
236. Watanabe M., Nobuta A., Tanaka J., Asaka M. An effect of K-Ras gene mutation on epidermal growth factor receptor signal transduction in panc-1 pancreatic carcinoma cells. Int. J. Cancer. 67:1996;264-268.
237. Werner M.H., Humphrey P.A., Bigner D.D., Bigner S.H. Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathol. 77:1988;196-201.
238. Westermark B., Carlhendrik H., Nister M. Platelet-derived growth factor in human glioma. Glia. 15:1995;257-263.
239. Westermark B., Nister M., Heldin C.H. Growth factors and oncogenes in human malignant glioma. Neurol. Clin. 3:1985;785-799.
240. Westphal M., Brunken M., Rhode E., Herrmann H.-D. Growth factors in cultured human glioma cells: different effects of FGF, EGF, and PDGF. Cancer Lett. 38:1988;283-296.
241. White E., Chiou S.K., Rao L., Sabbatini P., Lin H.J. Control of p53-dependent apoptosis by E1B, Bcl-2, and H-Ras proteins. Cold Spring Harbor Symp. Quant. Biol. 59:1994;395-402.
242. White M.A., Nicolette C., Minen A., Polverino A., Van Aelst L., Karin M., Wigler M. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-542.
243. Wiemels J., Tamaki S.J., Smith M.T. Antisense to Ras genes in acute myeloid leukemia. Proc. Am. Assoc. Cancer Res. 36:1995;A3072.
244. Wiestler O.D., Aguzzi A., Schneemann M., Eibl R., von Deimling A., Kleihues P. Oncogene complementation in fetal brain transplants. Cancer Res. 52:1992;3760-3767.
245. Willumsen B.M., Christensen A., Hubbert N.C., Papageorge A.G., Lowy D.R. The p21-Ras C-terminus in required for transformation and membrane association. Nature. 310:1984;583-586.
246. Willumsen B.M., Norris K., Papageorge A.G., Hubbert N.C., Lowy D.R. Harvey murine sarcoma virus p21-Ras protein: biological and biochemical significance of the cysteine nearest the carboxyl terminus. EMBO J. 3:1984;2581-2585.
247. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA. 84:1987;6899-6903.
248. Wynford-Thomas D. In vitro models of thyroid cancer. Cancer Surv. 16:1993;115-134.
249. Xing J., Ginty D.D., Greenberg M.E. Coupling of the Ras-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 273:1996;959-963.
250. Xu G.F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R., Weiss R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 62:1990;599-608.
251. Yamada N., Iwasa H., Kato M., Miyazono K. Enhanced expression of transforming growth factor (TGF)-beta and its type I and type II receptors in human gliobloastoma tissues. Proc. Am. Assoc. Cancer Res. 38:1997;A229.
252. Yan N., Ricca C., Fletcher J., Glover T., Seizinger B.R., Manne V. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res. 55:1995;3569-3575.
253. Yokoyama K., Goodwin G.W., Ghomashchi F., Glomset J.A., Gelb M.H. A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc. Natl. Acad. Sci. USA. 88:1991;5302-5306.
254. J.R. Youman, (Ed.), Neurological Surgery: A Comprehensive Reference Guide to the Diagnosis and Management of Neurosurgical Problems, 4th edn., W.B. Saunders, Philadelphia, 1996.
255. Young J.L., Miller R.W. Incidence of malignant tumors in United States children. J. Pediatr. 86:1975;254-258.
256. Zhang F.L., Kirschmeier P., Carr D., James L., Bond R.W., Wang L., Patton R., Windsor W.T., Syto R., Zhang R., Bishop W.R. Characterization of H-Ras, N-Ras, K-Ras-4A and K-Ras-4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase-1. Proc. Am. Assoc. Cancer Res. 38:1997;A351.
257. I.F. Pollack, M. Bredel, M. Erff, Pediatr. Neurosurg. (in press).